Jenna Smith, PA-C | |
50 Industrial Park Rd, Lake Ariel, PA 18436-5606 | |
(570) 213-0270 | |
Not Available |
Full Name | Jenna Smith |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 50 Industrial Park Rd, Lake Ariel, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447802343 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | MA060788 (Pennsylvania) | Secondary |
363A00000X | Physician Assistant | MA060788 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jenna Smith, PA-C 647 Morgan St, Dickson City, PA 18519-1507 Ph: () - | Jenna Smith, PA-C 50 Industrial Park Rd, Lake Ariel, PA 18436-5606 Ph: (570) 213-0270 |
News Archive
Australian researchers are on the road to the discovery of a new form of artificial human skin that could be a boon to burn victims and other patients needing skin grafts. At present the available skin grafts are only 1 millimeter thick and serve only to replace the top epidermis layer.
A new study suggests that natural proteins can be used to effectively test new replacement hip and knee joints in the laboratory. The work could help with improving design in order to reduce wear and tear and increase the lifespan of such prosthetics.
Fullerenes have attracted considerable attention in different fields of science since their discovery in 1985. Investigations of physical, chemical and biological properties of fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-dimensionality and electronic configurations make them an appealing subject in medicinal chemistry. Their unique carbon cage structure coupled with immense scope for derivatization make them a potential therapeutic agent.
Trophos and AFM-Telethon today announce that data from the pivotal clinical trial of Trophos' lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology annual meeting to be held in Philadelphia, PA, USA, from April 26 to May 3 2014.
› Verified 6 days ago